Literature summary for 3.5.1.23 extracted from

Bai, A.; Bielawska, A.; Rahmaniyan, M.; Kraveka, J.M.; Bielawski, J.; Hannun, Y.A.
Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites (2018), Bioorg. Med. Chem., 26, 6067-6075 .

Search for more literature for 3.5.1.23

Application

Application	Comment	Organism
pharmacology	enzyme inhibition may be beneficial in cancer therapy	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
(1R,2R)-2-N-(tetradecanoylamino)-1-(4'-nitrophenyl)-propyl-1,3-O,O-(N,N-dimethylamino)acetate dihydrochloride	i.e. LCL521 or Di-DMG-B13, is a lysosomotropic inhibitor of ACDase, inhibition mechanism, overview. Low dose of LCL521 (0.001 mM) effectively inhibits ACDase in cells, but the effects are transient. A higher dose of LCL521 (0.01 mM) causes profound decrease of sphingosine and increase of ceramide, but additionally affects the processing and regeneration of the ACDase protein, with biphasic and reversible effects on the expression of ACDase, which parallels the long term changes of cellular sphingosine and ceramide. Finally, the higher concentrations of LCL521 also inhibit dihydroceramide desaturase (DES-1, EC 1.14.19.17). LCL521 inhibits ACDase specifically among the ceramidases in vitro, which is reinforced by the lysosomal targeting	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining
lysosome	-	Homo sapiens	5764	-

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q13510	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
acute myeloid leukemia cell	-	Homo sapiens	-
breast adenocarcinoma cell	-	Homo sapiens	-
carcinoma cell	-	Homo sapiens	-
HL-60 cell	-	Homo sapiens	-
MCF-7 cell	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
aCDase	-	Homo sapiens
acid ceramidase	-	Homo sapiens

General Information

General Information	Comment	Organism
metabolism	the enzyme activity is vital to tumor cell biology	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)